A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus

NCT06097299 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

346

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus

Interventions

BIOLOGICAL: mRNA-1345
BIOLOGICAL: Placebo

Sponsor

ModernaTX, Inc.